Medically reviewed by Anita C. Chandrasekaran, MD Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and ...

By pausing DMARDs, you may be ‘starting the cascade of getting the patient into trouble by interrupting therapy that’s ...

A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...

Psoriatic arthritis (PsA) is an immune-mediated condition, and people with PsA may be at a higher risk of developing many neurological conditions. Psoriatic arthritis (PsA) is an immune-mediated ...

Psoriatic arthritis can affect any joint in the body, including the elbow. When joints are affected, symptoms may resemble other types of arthritis. Inflammatory arthritis happens when the immune ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term ...

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research. What are the most promising ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in psoriatic arthritis (PsA), the company has presented detailed data from ...